Design, synthesis and pharmacological characterization of new highly selective CRF2 antagonists: Development of 123I-K31440 as a potential SPECT ligand

Peptides

Volumn 23, Issue 3, 2002, Pages 453-460

  Ruhmann A ^a   Chapman, J ^a   Higelin, J ^b   Butscha, B ^b   Dautzenberg, F M ^b  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b Axovan Ltd   (Switzerland)

Author keywords

123I, iodine 123; aSvg 30 (antisauvagine 30); cAMP (adenosine 3 ; 5 cyclic monophosphate); CRF (corticotropin releasing factor); HEK (human embryonic kidney); Receptor imaging; RPHPLC (reverse phase HPLC); SPECT (single photon emission computed tomography); Svg (sauvagine); Ucn (urocortin)

Indexed keywords

ACETYL DEXTRO PHENYLALANYLHISTIDYLLEUCYLLEUCYLARGINYLLYSYLNORLEUCYLISOLEUCYLGLUTAMYLISOLEUCYLG LUTAMYLLYSYLGLUTAMINYLGLUTAMYLLYSYLGLUTAMYLLYSYLGLUTAMINYLGLUTAMINYLALANYLALANYL ASPARAGINYLASPARAGINYLARGINYLLEUCYLLEUCYLLEUCYLASPARTYLTHREONYLISOLEUCINE; ADENYLATE CYCLASE; ANTISAUVAGINE 30; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 BETA; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2ALPHA; CYCLIC AMP; DEXTRO PHENYLALANYLHISTIDYLLEUCYLLEUCYLARGINYLLYSYLNORLEUCYLISOLEUCYLGLUTAMYLISOLEUCYLG LUTAMYLLYSYLGLUTAMINYLGLUTAMYLLYSYLGLUTAMYLLYSYLGLUTAMINYLGLUTAMINYLALANYLALANYL ASPARAGINYLASPARAGINYLARGINYLLEUCYLLEUCYLLEUCYLASPARTYLTHREONYLISOLEUCINE; DEXTRO TYROSYLHISTIDYLLEUCYLLEUCYLARGINYLLYSYLNORLEUCYLISOLEUCYLGLUTAMYLISOLEUCYLGLUTAM YLLYSYLGLUTAMINYLGLUTAMYLLYSYLGLUTAMYLLYSYLGLUTAMINYLGLUTAMINYLARGINYLARGINYLASP ARAGINYLASPARAGINYLARGINYLLEUCYLLEUCYLLEUCYLASPARTYLTHREONYLISOLEUCINE; IODINE 123; METHIONINE; NORLEUCINE; PHENYLALANINE; SAUVAGINE; SAUVAGINE[11-40][ACETYL 11 DEXTRO TYROSINE 12 HISTIDINE 17 NORLEUCINE]; SAUVAGINE[11-40][ACETYL 11 DEXTRO TYROSINE 12 HISTIDINE 17 NORLEUCINE] I 123; TYROSINE; UNCLASSIFIED DRUG; UROCORTIN;

ACETYLATION; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL INTESTINE;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CELLS, CULTURED; CYCLIC AMP; DRUG DESIGN; DRUG STABILITY; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEQUENCE HOMOLOGY, AMINO ACID; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

MUS MUSCULUS;

EID: 0036172428     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(01)00640-4     Document Type: Article

References (37)

1. The role of corticotropin-releasing factor in depression and anxiety disorders
2. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice
3. Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biological activity, and in vivo application in animals
4. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress
5. Neurobiology of corticotropin releasing factor (CRF) receptors, and CRF-binding protein: Implications for the treatment of CNS disorders
6. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1)
7. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression
8. Stress and the Gastrointestinal Tract IV. Modulation of intestinal inflammation by stress: Basic mechanisms and clinical relevance
9. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2
10. Urocortin, corticotropin releasing factor-2 receptors, and energy balance
11. 2α receptors and the role of position 185 for receptor-ligand selectivity
12. Molecular biology of the CRH receptors- in the mood
13. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: Evidence for evolutionary differences
14. Potent, structurally constrained agonists, and competitive antagonists of corticotropin-releasing factor
15. 125I-Antisauvagine-30: A novel, and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors
16. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
17. Peripheral administration of CRF and urocortin: Effects on food intake and the HPA axis in the marsupial Sminthopsis crassicaudata
18. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor
19. Activation of urocortin transport into brain by leptin
20. 7TM receptors: The splicing on the cake
21. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
22. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: The CRF2γ receptor
23. 2β receptor mRNAs are differentially distributed between the rat central nervous system, and peripheral tissues
24. Stress and irritable bowel syndrome
25. Urocortin, and corticotropin-releasing factor receptor expression in the human colonic mucosa
26. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system
27. Peripheral urocortin delays gastric emptying: Role of CRF receptor 2
28. Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri
29. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart
30. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: Differential roles of CRF receptors 1 and 2
31. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors
32. Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling
33. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30
34. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development
35. Stress and gastrointestinal tract. II. Stress and intestinal barrier function
36. Corticotropin-releasing factor (CRF) family of ligands and their receptors
37. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release, and peripheral inflammation